Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling
This first-in-disease use of the GLP-1 agonist Liraglutide demonstrates its safety and tolerability in an unselected cohort of patients hospitalized with COVID-19 pneumonia across a range of clinical severities.
Authors
- Milena Karina Coló Brunialti (ORCID: https://orcid.org/0000-0003-2874-520X)
- Chien-Nien Chen
- Rudolf K.F. Oliveira (ORCID: https://orcid.org/0000-0002-2252-8119)
- Mariana Cardoso (ORCID: https://orcid.org/0000-0003-3670-5582)
- Colm McCabe (ORCID: https://orcid.org/0000-0002-0392-8838)
- Reinaldo Salomão (ORCID: https://orcid.org/0000-0003-1149-4598)
- Lan Zhao (ORCID: https://orcid.org/0000-0003-1177-5568)
- Eloara V.M. Ferreira (ORCID: https://orcid.org/0000-0002-3291-6473)
Institutions
- Hammersmith Hospital (GB)
- Royal Brompton Hospital (GB)
- Imperial College London (GB)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Infectious Disease Reports
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3390/idr17010005
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29